Gateway Bio

Antimicrobial resistance claims approximately 5 million lives annually. Gram-negative bacteria are at the centre of this crisis, accounting for 8 of the WHO's top 10 priority pathogens. Despite decades of investment, antibiotics continue to fail because resistance mechanisms, including efflux pumps, reduced membrane permeability, and biofilm formation, physically prevent drugs from reaching their intracellular target.

Gateway Bio solves this directly. Our proprietary nanocarrier transports antibiotic payloads inside bacterial cells, bypassing resistance mechanisms. The platform is compound-agnostic, compatible with existing and pipeline antibiotics, and its modular design enables partners to generate patent protection across successive lifecycle stages. Our proprietary production process ensures scalability at low cost, a critical differentiator in this market.